Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Phase of Trial: Phase III
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms guardian TM 7
- Sponsors Novo Nordisk
- 17 Feb 2017 Planned End Date changed from 1 Dec 2018 to 14 Dec 2018.
- 17 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 14 Dec 2018.
- 16 Dec 2016 Status changed from not yet recruiting to recruiting.